May 27

Agios begins AG-348 Phase 1 research to take care of PK deficiency Agios Pharmaceuticals.

, a head in the areas of cancer metabolism and inborn mistakes of metabolism , declared dose administration of AG-348 in a Phase 1 study in healthy volunteers today. AG-348 can be an available orally, potent, selective small molecule activator of pyruvate kinase-R , a metabolic enzyme, which, when mutated, prospects to pyruvate kinase deficiency, a rare, inherited hemolytic anemia. There is considerable unmet need among individuals with PK deficiency as there is absolutely no therapy available to treat the underlying disease. AG-348 is wholly owned by Agios, with the ongoing company maintaining full worldwide development and commercialization rights. Related StoriesCrucial change in single DNA foundation predisposes children to aggressive form of cancerCornell biomedical engineers develop 'super organic killer cells' to destroy cancer cells in lymph nodesNew findings reveal association between colorectal melanoma and cancer drug treatment ‘Today's announcement marks the initiation of our first clinical system in IEMs and our third while a organization,’ said David Schenkein, M.D., chief executive officer of Agios.In the 45-54 age group, the stroke rate is 192 % for African-Americans compared with 74 % for whites. That disparity in the incidence price evens out and adjustments as you monitor stroke in older Americans. Actually the racial variations reverse, so by the proper time they reach about age 80 and older, whites have a higher stroke rate weighed against blacks, Howard stated. It is not clear why the distinctions change with age, but it might have to do with different types of strokes occurring in various age groups. The end result is that particular subgroups are in greater risk and have to pay closer attention to their stroke-risk factors, stated George Howard, Dr.PH., a UAB professor of biostatistics and a REGARDS co-principal investigator.